Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Osimertinib

SKU: orb1305406

Description

Osimertinib (AZD-9291) is an oral, irreversible third-generation EGFR inhibitor designed to target the T790M resistance mutation in non-small cell lung cancer (NSCLC). It is widely used in preclinical research, demonstrating potent antitumor activity in both in vitro cell assays and in vivo xenograft models of EGFR-mutant NSCLC.

Research Area

Cardiovascular Research, Pharmacology & Drug Discovery, Signal Transduction

Images & Validation

−

Key Properties

−
CAS Number1421373-65-0
MW499.6
Purity>98%
FormulaC28H33N7O2
SMILESCN1C=C(C=2C1=CC=CC2)C3=NC(NC4=C(OC)C=C(N(CCN(C)C)C)C(NC(C=C)=O)=C4)=NC=C3
TargetKinase
SolubilitySoluble in DMSO (up to 40 mg/ml)

Bioactivity

−
Target IC50
MNK2:48.6 nM|EGFR (WT):493.8 nM|MNK1:324 nM|H1975 cells:1.78 μM|PC9 cells:0.66 μM|EGFR (exon 19 deletion):12.92 nM|EGFR (L858R/T790M):11.44 nM
In Vivo
In mutant EGFR cell lines, AZD9291 effectively inhibits cell proliferation.
In Vitro
In the EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models, oral administration of AZD9291 (5 mg/kg) effectively inhibits AKT and ERK signaling pathways as well as EGFR phosphorylation in tumors, leading to tumor regression.
Cell Research
AZD-9291 is dissolved in DMSO and stored, and then diluted with appropriate medium before use. PC-9 cells are seeded into T75 flasks (5×105 cells/flask) in RPMI growth media and incubated at 37°C, 5% CO2. The following day the media is replaced with media supplemented with a concentration of EGFR inhibitor equal to the EC50 concentration predetermined in PC-9 cells. Media changes are carried out every 2-3 days and resistant clones allowed to grow to 80% confluency prior to the cells being trypsinised and reseeded at the original seeding density in media containing twice the concentration of EGFR inhibitor. Dose escalations are continued until a final concentration of 1.5 μM Gefitinib, 1.5 μM Afatinib, 1.5 μM WZ4002 or 160 nM AZD-9291 are achieved.

Storage & Handling

−
Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

−
AZD-9291

Similar Products

−
  • AZD 4205 [orb573442]

    >98%

    2091134-68-6

    521.601

    C25H31N9O2

    250 mg, 100 mg, 1 g
  • Osimertinib dimer [orb3135414]

    2564638-97-5

    1000.22

    C56H67N14O4

    50 mg, 10 mg
  • ER ligand-14 [orb3210103]

    10 mg, 50 mg
  • SG-55 [orb3211209]

    10 mg, 50 mg
  • ER ligand-14-PEG3-Boc [orb3177173]

    50 mg, 10 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Key Properties

−
No computed properties available.

Protocol Information

Available Sizes

Select a size below

10 mg
$ 170.00
50 mg
$ 290.00
DispatchUsually dispatched within 5-10 working days
Bulk Enquiry